SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Inclusion Criteria: * Signed written consent form; * age ≥18 years old; * randomization within 2-8 weeks after surgery; * Performance status of the US Eastern Cancer Cooperative Group (ECOG) score 0-1; * pathologically diagnosed as stage III colon or rectal adenocarcinoma patient; * Accept effective contraceptive measures; * postmenopausal women; pregnancy test negative 72 hours before randomization; * R0 resection. Exclusion Criteria: * primary tumor metastasis (including tumor cells in the ascites or the occurrence of peritoneal metastasis); * presence of clinical relevant cardiovascular disease; * presence of disease history of central nervous system, or evidence confirmed subjects suffering from central nervous system diseases; * presence of grade 3 (or over grade 3) peripheral neuropathy, according to the common adverse event evaluation criteria (CTCAE) v. 3.0; * post-operative radiotherapy must be implemented in patients according to researchers' assessment,; * presence of any unresolved toxicity left from previous anti-cancer treatment left \> grade 2 according to CTCAE, except hair loss; * simultaneous use of targeted therapeutic drugs, such as anti-vascular endothelial growth factor (VEGF) monoclonal antibody, or anti-epidermal growth factor receptor (EGFR) monoclonal antibody; * brain metastases or meningeal metastases; * Insufficiency of bone marrow reserve capacity, the presence of neutrophils absolute count ≤ 1.5 × 109 / L or platelet count ≤ 75 × 109 / L, or …